South Korea begins supply of Gilead's remdesivir
01 July, 2020
South Korea has started distributing stocks and shares of the COVID-19 treatment remdesivir which were donated by Gilead Sciences, and plans to begin talks to buy more supplies found in August, its disease control organization said.
"Patients who meet the criteria for remdesivir happen to be limited to severe patients with pneumonia and looking for oxygen therapy," the Korea Centres for Disease Control and Avoidance (KCDC) said in a good statement.
It didn't disclose just how many doses have been donated by the American organization.
Gilead said on Monday (Jun 29) it has priced remdesivir in US$390 per vial in america and other developed countries and agreed to send nearly all of its supply of the medicine to the US over the next 90 days.
Based on current treatment habits that compatible US$2,340 every patient.
South Korea has reported a complete of 12,850 coronavirus cases by Tuesday with 282 deaths.
Source:
TAG(s):